Sanofi: Genzyme expands collaboration with Alnylam
BUY, Fair Value EUR88,5 (+20%)
Sanofi and Alnylam have inked a wide collaborative agreement which gives Genzyme expanded access to Alnylam’s pipeline that is targeting several rare genetic diseases. Rights in NA and Europe are usually either excluded or shared however. Genzyme is making a USD700m investment in Alnylam. It is too early to adjust our model as the opportunity is more medium term.
Full report available to subscribers
Please contact firstname.lastname@example.org